Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of AML in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 26- ALFA 9801
Brief Summary: Randomized comparison of standard induction treatment with daunorubicin for 3 days and Idarubicin for 3 or 4 days in adult AML patients between 50 and 70 years. Study of maintenance treatment with IL2


Options:
A: Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cytosin-Arabinosid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: All-trans Retinoid acid; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Daunorubicine; Assigned to Arm(s): N/A
C: Arm Label: Arm1 = Aracytine + Daunorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy (Aracytine + Daunorubicin) | Arm Label: Arm 3 = Aracytine And Idarubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy (Aracytine + Daunorubicin) | Arm Label: Arm 2 = Aracytine And Idarubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy (Aracytine + Daunorubicin) | Intervention Type: DRUG; Name: chemotherapy (Aracytine + Daunorubicin); Assigned to Arm(s): Arm1 = Aracytine + Daunorubicin | Intervention Type: DRUG; Name: chemotherapy (Aracytine + Daunorubicin); Assigned to Arm(s): Arm 2 = Aracytine And Idarubicin | Intervention Type: DRUG; Name: chemotherapy (Aracytine + Daunorubicin); Assigned to Arm(s): Arm 3 = Aracytine And Idarubicin
D: Arm Label: Standard Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then Allogeneic HCT or no Consolidation; Type: ACTIVE_COMPARATOR; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Arm Label: High-dose Daunorubicin Then Allogeneic HCT or no Consolidation; Type: EXPERIMENTAL; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Intervention Type: BIOLOGICAL; Name: sargramostim; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: gemtuzumab ozogamicin (GO); Assigned to Arm(s): High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: Daunorubicin; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Autologous HCT; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Allogeneic HCT; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Allogeneic HCT or no Consolidation

Answer: C